Clinical trial
Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery…
NCT00137332 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00137332 |
|---|---|
| Title | Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease |
| Official title | A Study of the Effects GAP-486 on Ventricular Tachyarrhythmia Induction |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Arrhythmia |
| Intervention type | Drug |
| Interventions | GAP-486 (ZP-123), 0.9% Sodium Chloride, USP |
| Enrollment | 90 |
| Start date | Nov 1, 2005 |
| Completion | Oct 1, 2006 |
| First posted | Aug 29, 2005 |
| Last update posted | Dec 10, 2007 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: